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Abstract Cerebrovascular lesions related to congophilic
amyloid angiopathy (CAA) often accompany deposition of
b-amyloid (Ab) in Alzheimer’s disease (AD), leading to
disturbed cerebral blood flow and cognitive dysfunction,
posing the question how cerebrovascular pathology con-
tributes to the pathology of AD. To address this question,
we characterised the morphology, biochemistry and func-
tionality of brain blood vessels in transgenic arctic
b-amyloid (arcAb) mice expressing human amyloid pre-
cursor protein (APP) with both the familial AD-causing
Swedish and Arctic mutations; these mice are characterised
by strong CAA pathology. Mice were analysed at early,
mid and late-stage pathology. Expression of the glucose
transporter GLUT1 at the blood–brain barrier (BBB) was
significantly decreased and paralleled by impaired in vivo
blood-to-brain glucose transport and reduced cerebral lac-
tate release during neuronal activation from mid-stage
pathology onwards. Reductions in astrocytic GLUT1 and
lactate transporters, as well as retraction of astrocyte end-
feet and swelling consistent with neurovascular uncoupling,
preceded wide-spread b-amyloid plaque pathology. We
show that CAA at later disease stages is accompanied by
severe morphological alterations of brain blood vessels
including stenoses, BBB leakages and the loss of vascular
smooth muscle cells (SMCs). Together, our data establish
that cerebrovascular and astrocytic pathology are paralleled
by impaired cerebral metabolism in arcAb mice, and that
astrocyte alterations occur already at premature stages of
pathology, suggesting that astrocyte dysfunction can con-
tribute to early behavioural and cognitive impairments seen
in these mice.
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Introduction
Vascular accumulation of b-amyloid (Ab) results in con-
gophilic amyloid angiopathy (CAA), a vascular lesion
diagnosed as part of b-amyloid pathology in up to 90% of
post-mortem brains with a neuropathological diagnosis of
Alzheimer’s disease (AD) [57]. CAA is associated with a
plethora of abnormalities and malfunctioning of the cere-
brovasculature [6, 15, 40, 49, 52, 64] including ruptures of
the vessel walls causing microhaemorrhages and lesions of
the blood–brain barrier (BBB), resulting in inflammation,
vascular oedema and uncontrolled influx of peripheral
blood components into the brain parenchyma [65]. As a
result of CAA, vascular basement membranes (VBM)
thicken and smooth muscle cells (SMC) degenerate, jointly
leading to impaired cerebral blood flow (CBF) [15, 18, 40].
Physiological functions of the cerebral vasculature are
compromised early, possibly even preceding the onset of
AD pathology including the onset of CAA, and raising the
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possibility of an early involvement of vascular dysfunction
in the pathophysiology of the disease with disturbances in
angiogenesis [11, 54]. Cerebral hypoperfusion and hypo-
metabolism occur in patients with mild cognitive
impairment (MCI), and were also observed in transgenic
mouse models of AD in which they precede the onset of
b-amyloid plaque pathology [5, 10]. While vascular and
metabolic disorders including atherosclerosis and diabetes
can strongly impair cerebral circulation [25], neurotoxic
soluble Ab species can also diminish performance of the
cerebral vasculature [16, 18], presumably already at early
and pre-pathological stages of b-amyloid pathology. As a
consequence, Ab-related disruption of brain blood flow
could lead to neuronal impairments by compromising a
steady vascular supply of essential metabolic precursors
such as oxygen, amino acids and glucose [4, 24, 65], as
well as by decreasing cerebral lymphatic drainage of
metabolic products [58, 59]. Astrocytes play a pivotal role
in regulating these functions by mediating signalling and
nutrient exchange between neurons and vascular endothe-
lium [1, 23] via astrocyte endfeet that contain numerous
nutrient transporters including the glucose transporter
GLUT1 and the monocarboxylate transporter 1 (MCT1), in
addition to many receptors essential for signal transduction
[1, 41]. Interactions of astrocyte endfeet with the VBM are
mediated via the dystroglycan protein complex that binds
to laminin and neuronal-expressed neurexin [2, 56, 63].
Astrocyte endfeet can retract and swell during pathological
conditions including neuroinflammation in multiple scle-
rosis and in experimental autoimmune encephalomyelitis
[63]. Because both astrogliosis surrounding b-amyloid
plaques and neuroinflammation occur in AD, alterations in
astrocyte endfeet structure and function are likely to be
present [13, 63, 64]; such changes consistent with loss of
contact between astrocyte endfeet and the cerebrovascu-
lature were indeed observed in a transgenic mouse model
of AD [61]. To further understand the role of the cere-
brovasculature and astrocytes as well as their influence on
cerebral metabolism in b-amyloid pathology, we charac-
terised cerebral blood vessels and astrocytes in transgenic
arcAb mice expressing both the Swedish and Arctic APP
mutations. This mouse model exhibits severe vascular AD
pathology with significant electrophysiological and
behavioural deficits preceding b-amyloid deposition [28,
35]. The Swedish double mutation (K670N and M671L)
together with the arctic mutation (E693G) leads to an
over-production of aggregation-prone Ab42 and accumu-
lation of Ab at brain blood vessels [28, 35]. Similar as
was described for other mouse models of AD [22, 42, 55,
62], our studies identified severe morphological and bio-
chemical abnormalities of CAA-affected vessels including
stenoses, leakages, loss of vascular smooth muscle cells,
and decreased GLUT1 expression. We also observed a
unique astrocytic pathology commencing at the early dis-
ease stages. These included reduced GLUT1 and MCT1
expression, decreased astrocytic release of lactate in vivo
and ex vivo, increased laminin secretion and retraction and
swelling of astrocyte endfeet surrounding diffuse and vas-
cular Ab depositions, signs of neurovascular uncoupling
and BBB disruption. In vivo microdialysis revealed severe
reductions in brain glucose concentrations at baseline
during neuronal stimulation and impaired blood-to-brain
glucose uptake. These findings establish an astrocytic
involvement in the early stages of the cerebrovascular
and metabolic pathology in this transgenic mouse model
of AD.
Materials and methods
Animals
ArcAb mice were produced as described previously by
Knobloch and colleagues [28]. Non-transgenic littermates
were used as controls when specified. All animals were
housed 3–5 per cage and had access to food and water
ad libitum under a 12-h light/dark cycle. All in vivo
experiments conducted complied with Swiss federal and
cantonal law and were performed with the approval of the
Swiss Veterinary Council, approval number 47/2008, 3781.
Classification of disease pathology
Transgenic arcAb mice were grouped according to the dis-
ease pathology in the following groups: early-stage
pathology: 6 months old, mid-stage pathology: 9–13 months
old and late-stage disease pathology: 16–22 months old.
Disease stage pathology was based on overall cerebral Ab
plaque burden including CAA and cognitive performance
according to Knobloch et al. [28].
Perfusion of mice and collection of brain material
Mice were deeply anaesthetised using a cocktail of 1.25%
ketamine and 0.25% xylazine. Mice used for histochem-
istry purposes were transcardially perfused with ice-cold
PBS (10 mM Na2HPO4, 2.5 mM NaH2PO4, 150 mM
NaCl, 3 mM KCl) followed by ice-cold paraformaldehyde
(PFA) 4.0% in phosphate buffer 0.15 M (Na2HPO4 ?
NaH2PO4 in double-distilled water), pH 7.4. Brains were
incubated in PFA 4.0% in PBS for 4 h at 4C followed by
incubation in sucrose 30% in PBS for 24–36 h. Mice
serving biochemistry purposes were transcardially perfused
with ice-cold PBS only. Hippocampi were dissected out
and cortices, hippocampi and cerebella were separately
snap-frozen in liquid nitrogen and stored at -80C.
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Vascular corrosion casts and scanning electron
microscopy
All procedures were carried out as described previously [34].
In brief, anaesthetised mice (100 mg/kg pentobarbital) were
first perfused with artificial cerebrospinal fluid (aCSF) con-
taining heparin followed by a perfusion with 4% PFA in PBS.
Subsequently, mice were perfused with the casting resin PU4ii
(vasQtec, Switzerland). After a curing period of 7 days, soft
tissue was macerated in 7.5% potassium hydroxide at 50C for
24–72 h and the bones decalcified in 5% formic acid at 50C
for 24–72 h. Vascular corrosion casts were washed with
water, dried by lyophilisation and sputter-coated with gold
particles for scanning electron microscopy (SEM) purposes.
Extraction of membrane brain proteins
Working on ice, brain materials (hippocampi and cortices)
were homogenised separately in homogenisation buffer
[Tris-HCl 10 mM, pH 7.4, EDTA 1.0 mM, sucrose 250 mM
and protease inhibitors (Complete, Roche, Switzerland)]
with 30 strokes using a glass Dounce homogeniser with
Teflon pestle (Wheaton, USA). Homogenates were centri-
fuged at 9009g and 4C for 10 min. The formed supernatants
were subsequently centrifuged at 110,0009g and 4C for
75 min. Supernatants were discarded and the pellets dis-
solved in solubilisation buffer [Tris-HCl 10 mM, pH 7.4,
EDTA 1.0 mM, Triton X-100 0.50%, sodium deoxycholate
0.50% and protease inhibitors (Complete, Roche, Switzer-
land)] by continuous rotation at 4C for 1 h. The dissolved
pellets were centrifuged at 14,0009g and 4C for 10 min.
Supernatants were collected and protein concentrations
measured using the Pierce BCA Protein Assay Kit (Thermo
Scientific, Rockford, IL, USA).
Immunoblotting
Equal amounts of total protein or equal volumes of cell cul-
ture media were subjected to separation on 10–20% Tricine
gels (Invitrogen, Basel, Switzerland), blotted on nitrocellu-
lose membranes Immobilon-P PVDF membranes (0.45 lm,
Millipore, Switzerland). The immunoblot was then incubated
with primary antibodies followed by incubation with HRP-
tagged secondary antibodies. Detection was performed using
chemiluminescence visualised using ECL WB reagents
(Amersham Pharmacia, GE, Germany) or SuperSignal West
Dura Extended Duration reagents (Pierce, Rockford, IL,
USA) on BIOMAX films (GE, Germany).
Immunohistochemistry
Paraformaldehyde-fixed and cryoprotected brains were cut
into 30 lm thick slices at*-80C using a microtome (Leica
Jung HN40) and kept at -20C in an anti-freeze solution
(phosphate buffer 0.50 M in MilliQ water:ethylenegly-
col:glycerol = 1.3:1:1) until staining was performed. All
immunohistochemical stainings were executed using the
free-floating method. Washing steps were carried out
between all incubations using washing buffer (TBS pH 7.4
containing 0.2% Triton X-100) at RT. Antigen retrieval was
performed when required using the proteinase K antigen
retrieval method [incubation of sections in proteinase K
solution (proteinase K 20 lg/ml in Tris base 50 mM ?
EDTA 1.0 mM, pH 8.0)] at 37C for 7 min. Slices were
blocked for 1 h at RT using blocking buffer (5.0% goat serum
5.0% donkey serum in washing buffer). Blocked slices were
incubated overnight at 4C with slight agitation in primary
antibody incubation buffer (2.5% goat serum and 2.5%
donkey serum in washing buffer) containing the primary
antibody/antibodies. Subsequently, secondary antibody
incubations were carried out for 2 h at RT. Slices were
washed in washing buffer, mounted on chrom-gelatin-coated
microscopy slides (SuperFrost Plus, Menzel, Braunschweig,
Germany) and glass-covered using Hydromount (National
Diagnostics, Hull, UK).
Image analysis
Fluorescent immunohistochemical images were acquired
on a Leica DM4000B microscope using an Olympus DP71
colour digital camera and newCAST software (Visiop-
harm, Copenhagen, Denmark). Image analysis was carried
out with ImageJ software (NIH, USA).
High-resolution imaging was performed using a TCS/SP2
Leica confocal laser scanning microscope (Leica, Wetzlar,
Germany) with 639 objective (water, NA: 1.2) where men-
tioned in the figure legends. All confocal images are maximal
intensity projections of z stacks composed of multiple images.
Trypan Blue BBB leakage experiments
Mice received an intraperitoneal injection of 200 ll of a
0.4% Trypan Blue solution in 0.85% saline (Gibco, Swit-
zerland). Thirty minutes after Trypan Blue administration,
mice were perfused and their brains processed for histo-
logical analysis as described above. Trypan Blue was
visualised using immunofluorescence with excitation and
emission wavelengths at 642 and 660 nm, respectively.
Protocol adapted from Persson et al. [39].
Prussian Blue and Thioflavin S stain for detection
of haemorrhages and CAA
Haemorrhages were visualised using the Prussian Blue
stain method on free-floating brain sections. Free-floating
brain sections were incubated in a mixture of equal
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volumes of 10% potassium ferrocyanide (K4Fe(CN)6 tri-
hydrate) in d.d. H2O and 20% hydrochloric acid (HCl) in
d.d. H2O for 30 min. Brain sections were subsequently
washed with d.d. H2O, counterstained with nuclear fast red
solution for 10 min and washed with d.d. H2O. To co-stain
for CAA/fibrillar Ab, sections were subsequently incubated
in a 0.25% aqueous solution of potassium permanganate
for 20 min, washed, incubated in an aqueous solution of
2% potassium disulphite and 1% oxalic acid for 2 min;
washed, incubated in 0.25% acetic acid for 5 s; washed,
incubated in a 50% ethanol solution of 0.0125% Thioflavin
S; washed and mounted as described above. All chemicals
were purchased from Sigma-Aldrich, Switzerland. Prussian
Blue was detected using bright field microscopy; ThioS
using fluorescence microscopy with excitation and emis-
sion wavelengths at 490 and 514 nm, respectively.
Ex vivo astrocyte cultures
Astrocytes were cultured from early and mid-stage pathol-
ogy TG and arcAb NTG mice. For the isolation of adult
mouse brain astrocytes, mice were deeply anaesthetised
using a cocktail of 1.25% ketamine and 0.25% xylazine.
Working on ice, meninges and cerebellum ? brain stem
were carefully removed, the remaining brain tissue minced
into small pieces and homogenised in culture medium
(DMEM/F12 containing L-glutamine 2 mM, FCS 10%,
PenStrep 1.0% (all from Invitrogen, Switzerland)) using a
glass homogeniser with Teflon pestle (Wheaton, USA).
Brain homogenates were cultured in poly-L-lysine-coated
75 cm2 cell culture flasks (TPP, Switzerland) at 37C, 5.0%
CO2 and 100% humidity. After the cells had reached
80–90% confluence (about 4–6 weeks), the oligodendro-
cytes layer was detached and removed by shaking of the
culture flasks and the medium aspirated. Trypsin/EDTA
buffer (Invitrogen, Switzerland) was added to the remaining
astrocytes and left for 2 min at 37C. Culture medium was
added and the astrocytes in the medium centrifuged at
1,250 rpm for 10 min. Pellets were homogenised in a fresh
culture medium and astrocytes were seeded in poly-L-
lysine-coated 6-well culture plates (TPP, Switzerland),
1.0 9 106 cells in 2 ml culture medium per well or 10 cm
culture Petri dishes (2.0 9 106 cells in 10 ml culture med-
ium per dish). Cells were grown to 80–90% confluence and
split or frozen and stored in liquid nitrogen at -196C.
Microdialysis surgery
Surgery for microdialysis studies was performed in mid-stage
pathology arcAb mice which were deeply anaesthetised by an
intraperitoneal injection (100 ll/10 g body weight) of a
cocktail consisting of fentanyl 50 ll/ml, midazolam 5.0 mg/
ml and medetomidin 1 mg/ml in 0.9% sterile saline. To
prevent drying of the cornea, an eye cream (Viscotears,
carbomerum 980, 2.0 mg) was applied onto the eyes. Body
temperature was controlled throughout all the surgical pro-
cedures by means of a rectal probe connected to a whole body
heating pad set at 37C. Mice were placed in a stereotactic
frame and the skull was exposed. A small hole was drilled to
allow the implantation of a microdialysis guide cannula
(CMA/7, Aurora Borealis Control B.V. Schoonebeek, The
Netherlands) in the hippocampus [relative to bregma (in
mm): AP: -3.1; L: ?3.0; V: -2.0]. Two support screws were
placed to hold the guide, which was glued to the skull with
dental acrylic cement (Pattern Resin, GC Europe, Switzer-
land). A subcutaneous injection of the analgesic Metacam
(1 lg/g body weight) was administered directly after surgery
followed by an antidote (intraperitoneal injection of 100 ll/
10 g body weight of a mixture consisting of naloxon 0.4 mg/
ml, flumazenil 0.1 mg/ml and atipamezol 5.0 mg/ml in 0.9%
sterile saline) to antagonise the anaesthetic.
Microdialysis experiments
Eighteen hours prior to the experiment, the microdialysis
probe (CMA/7, cut-off 6 kDa, membrane length 1.0 mm,
Aurora Borealis Control B.V., Schoonebeek, the Nether-
lands) was inserted into the guide cannula. The inlet of the
microdialysis probe was connected by fluorinated ethylene
propylene tubing (FEP tubing, CMA, Sweden) to a syringe
pump (Beehive, Bas Technicol, Congleton, UK). The probe
was perfused with artificial extracellular fluid (aCSF, com-
position in mM: NaCl 145; KCl 2.7; CaCl2 1.2; MgCl2 1.0 in
a 2 mM phosphate buffer, pH 7.4) at a flow rate of 1 ll/min.
The outlet was connected to another piece of FEP tubing with
sample vial attached. Eighteen hours after insertion and start
of perfusion of the probe, the actual experiment was started
(between 08:00 and 09:00 a.m.). To assess the baseline
glucose differences between TG and NTG arcAb mice, 20
samples with 30-min intervals were collected. Each sample
vial was put on dry ice directly after the sampling time was
over and exchanged for a new, empty one. For glucose
uptake measurements, mice were fasted for 12 h prior to the
experiment. After collection of three 30-min interval
microdialysis samples (for baseline glucose measurements),
mice were given an intraperitoneal injection of 250 mg
glucose in PBS/kg body weight during continuous microdi-
alysis sampling. Twelve 5-min interval microdialysis
samples were collected, followed by four 30-min samples.
Fifteen min before the sampling time of the last 30-min
interval sample had ended, aCSF perfusate was changed to
aCSF containing potassium chloride (KCl) 120 mM using a
liquid switch (CMA, Sweden). These 15 min were calcu-
lated based on the dead volume of the FEP tubing and
microdialysis probe in- and outlet. Two 5-min samples were
collected after which an intraperitoneal injection of 250 mg
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glucose in PBS/kg body weight was given during continuous
microdialysis sampling. Twelve more 5-min interval sam-
ples were taken followed by two 30-min collections. Each
sample vial was put on dry ice immediately after its sampling
time was over and exchanged for a new, empty one.
Glucose and lactate assays
Glucose was measured using the Amplex Red Glucose/
Glucose Oxidase Assay Kit from Invitrogen, Switzerland.
Microdialysis samples were diluted 1:5 and blood samples
1:20, cell culture media were used undiluted; processing of
samples and assay was performed according to the manu-
facturer’s directions. Lactate assays were performed with
an in-house made lactate assay: cell culture media samples
were used undiluted whereas microdialysis samples were
diluted 1:10 in reaction buffer (KH2PO4 10 mM, pH 6.6,
with flavin adenine dinucleotide 0.01 mM) and 50 ll of
these samples and 50 ll of lactate calibration standards
(L-lactate, Sigma-Aldrich, Switzerland) were mixed with
50 ll lactate assay reaction mix [5 ml lactate reaction
mix contained 30 ll Amplex Red 10 mM (Invitrogen,
Switzerland), 80 ll horseradish peroxidase 10 U/ml
(Invitrogen, Switzerland), 30 ll lactate oxidase 100 U/ml
(Sigma-Aldrich, Switzerland) in 4.86 ml reaction buffer]
followed by a 20 min incubation at 37C. Fluorescence
was read using a fluorescence reader (SpectraMax Gemini
XS, Bucher Biotec AG, Switzerland). Excitation and
emission were set at 540 and 590 nm, respectively.
Primary antibodies
Primary antibodies used for immunohistochemistry and
western blotting: glucose transporter 1 (GLUT1, Alpha
Diagnostic, GT11-A; GLUT1, Abcam, ab40084), glucose
transporter 3 (GLUT3, Alpha Diagnostic, GT31-A), endo-
thelial cells (CD31/PECAM1, BD Pharmingen, 553370),
APP/Ab (6E10, Covance/Signet, SIG-39300), Ab (in-house
produced antibody recognising fibrillar Ab), laminin (Sigma-
Aldrich, L9393), b actin (Abcam, ab6276), lactate transporter
1/monocarboxylate transporter 1 (MCT1, Alpha Diagnostic,
MCT-13A), glial fibrillary acidic protein (GFAP, Advanced
Immunochemical Inc., 031223), alpha smooth muscle actin
(Sigma-Aldrich, A2547), b dystroglycan (Abcam, ab49515).
Results
Decreased endothelial and astrocytic GLUT1
expression in mid-stage arcAb mice
Western blot analysis of cortex and brain homogenates from
mid-stage TG arcAb mice and their NTG littermates
revealed that the expression of the endothelial GLUT1
protein (55 kDa isoform) was reduced in the TG animals
(Fig. 1d). This phenomenon was observed starting in TG
mice around mid-stage disease pathology, an age group at
which diffuse and vascular Ab plaque pathology becomes
wide-spread in our TG arcAb mice. The decrease in GLUT1
protein expression was more pronounced in the hippo-
campus than in the cortex. Moreover, ex vivo astrocytic
cultures from these mid-stage TG arcAb mice were found to
express less GLUT1 protein (45 kDa isoform) as compared
to astrocytes from their NTG littermates (Fig. 3a). Immu-
nohistochemical staining of free-floating brain sections
revealed that the expression of GLUT1 protein but not that
of the endothelial marker CD31 was significantly reduced
mainly on blood vessels affected by CAA (Fig. 1a, c). Yet,
in brain regions with a dense population of diffuse plaques
GLUT1 staining pattern on blood vessels was affected as
well, being more intervallic in contrast to the continuous
expression of CD31 (Fig. 1b). No differences in expression
level of the neuronal GLUT3 protein between TG and NTG
brain homogenates were observed (Fig. 1d). The apparent
difference in GLUT1 reduction between biochemical anal-
ysis (Fig. 1d) and histochemical quantification (Fig. 1c) is
due to the fact that biochemical analysis was performed on
whole brain extracts (excluding cerebellum) and histo-
chemical quantification took account of GLUT1 reduction
on CAA-affected vessels only. As can be seen from Fig. 1b
also in areas with high abundance of diffuse Ab plaques
endothelial GLUT1 was decreased, an additional decrease
that has to be added to the GLUT1 reduction as found on
CAA-laden vessels.
Reduced brain baseline glucose concentrations
and impaired blood-to-brain glucose uptake
in mid-stage arcAb mice
To investigate whether reduced GLUT1 protein expression
would cause decreased glucose concentration in hippocampal
extracellular fluid (ECF), in vivo hippocampal microdialysis
was performed. Baseline hippocampal glucose concentra-
tions measured continuously over 10 h were found to be
lower in TG animals as compared to their NTG littermates
(Fig. 2a). No such differences were found in plasma glucose
levels (Fig. 2b) and a systemic cause for the hippocampal
glucose deficiencies as present in the TG animals could hence
be ruled out. To investigate if these chronically decreased
ECF glucose baseline concentrations in the TG arcAb mice
were indeed caused by insufficient blood-to-brain glucose
uptake due to decreased GLUT1 expression, glucose uptake
was assessed (Fig. 2c). After a 12 h period of fasting and
collection of four 30-min interval microdialysis samples (for
baseline glucose measurements), mice were given an intra-
peritoneal injection of 250 mg glucose/kg body weight
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during continuous microdialysis sampling (Fig. 2c, sample 5,
single arrow). Fifteen 5-min interval microdialysis samples
were collected (samples 5–19), followed by four 30-min
samples (samples 20–23). Whereas in the microdialysate of
the NTG animals first a clear fall in glucose was measured in
the 5-min interval microdialysate sample collected during
and directly after injection of glucose (sample 5, single arrow)
and then a steep rise to a new glucose concentration plateau
was established, no such change in the glucose concentration
profile was seen in the TG arcAb mice. Contrary to these
findings, retrodialysis of 120 mM potassium chloride (KCl)
to stimulate neuronal activity combined with intraperitoneal
administration of 250 mg glucose/kg body weight (Fig. 2c,
sample 24, double arrows) led to a sharp fall and then steep
rise in glucose concentration in the microdialysate of both
NTG and TG mice.
Impaired lactate release upon neuronal stimulation
and reduced expression of the astrocytic lactate
transporter MCT1 in mid-stage arcAb mice
To analyse the consequences of impaired glucose con-
centration profiles on neuronal functioning, the release of
lactate during neuronal stimulation was assessed. Lactate
Fig. 1 Endothelial GLUT1 but not neuronal GLUT3 protein expres-
sion and basal glucose levels are decreased in the TG arcAb mouse
brain from mid-stage pathology onwards. a Immunohistochemical
staining of a representative cortical brain section showing GLUT1
protein expression on CAA and non-CAA blood vessels in a mid-
stage TG arcAb mouse. Reduced GLUT1 immuno-staining (arrow)
on a CAA-vessel (stained with antibody 6E10, arrow) can be seen.
However, CD31—a marker for endothelial cells—was not affected
and eventual impaired staining for GLUT1 due to antigen-masking by
CAA (arrow) could be ruled out. b Immunohistochemical staining of
a representative cortical brain section of a mid-stage arcAb mouse
shows that in areas with dense presence of diffuse Ab plaques also
non-CAA vessels had reduced GLUT1 protein expression, whereas
CD31 staining was preserved on these vessels (arrows). CD31 was
found to be continuously expressed on the whole length of the vessels
in contrast to GLUT1 which showed interruptions in the staining
pattern (outlined section). c Statistical analysis of CD31 and GLUT1
expression on CAA-vessels in mid-stage arcAb mice. Immunostain-
ing for GLUT1 was significantly lower on these CAA-vessels as
compared to the CD31 staining. Student’s t test, p = 0.0004 (n = 35
CAA vessels). d Western blots of hippocampus and cortex of mid-
stage TG arcAb mice and NTG littermates demonstrating that the
endothelial GLUT1 protein expression (55 kDa) was reduced in TG
animals as compared to their NTG littermates. No differences were
found in the levels of the neuronal GLUT3 protein. Scale bar
a 100 lm; b 300 lm
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is derived from glucose and released by astrocytes upon
uptake of neuronal-secreted glutamate in the synaptic
cleft during neuronal stimulation [32, 37, 38]. Lactate was
measured in the same microdialysate samples as collected
for glucose uptake analyses (Fig. 2d). As can be seen
from Fig. 2d, baseline lactate levels were not different
between TG animals and their NTG littermates and not
affected by intraperitoneal administration of glucose
(sample 5, single arrow). However, retrodialysis of
120 mM KCl led to a fast and steep increase in lactate
levels in the microdialysate of NTG animals, a response
which was less pronounced (sample 24, double arrows)
and more protracted in the TG mice (samples 24–27).
This finding prompted us to further study the possibility
of a deficiency in lactate release by arcAb astrocytes. To
this aim, the expression of the astrocytic lactate trans-
porter monocarboxylate transporter 1 (MCT1)—which
transports lactate from the astrocyte cytoplasm into the
ECF where it can be taken up by neurons—was assessed
as well as the concentration of lactate released in culture
medium of ex vivo-cultured astrocytes derived from the
same cohort of mid-stage arcAb mice. A strongly reduced
expression of the lactate transporter was found in
the astrocyte lysates as demonstrated by WB (Fig. 3a) as
was a significantly decreased lactate release ex vivo
(Fig. 3b).
Fig. 2 Blood-to-brain glucose uptake and astrocytic lactate release
upon neuronal stimulation are impaired in TG arcAb mouse brain
starting at mid-stage pathology. a Lower baseline glucose concentra-
tion profile in hippocampal ECF microdialysate of mid-stage TG
arcAb mice as compared to their NTG littermates. Microdialysis
samples were taken in 30-min intervals over 10 h. On average
baseline hippocampal glucose was about 30% lower in TG animals as
compared to their NTG littermates. Note the higher degree of intra-
individual deviation in the TG animals, possibly due to the
heterogeneity of CAA and/or Ab plaque load in this group. b No
differences were found in plasma glucose levels between TG arcAb
mice and their NTG littermates. Blood was withdrawn from the tail
vein of the mice after an 8-h period of fasting. Mean plasma glucose
concentration for both TG and NTG animals was around 3.5 mmol/l.
c Graph illustrating impaired rise in glucose in hippocampal ECF of
TG arcAb mice upon systemic administration of glucose alone
(sample 5, single arrow) and in combination with neuronal stimula-
tion using potassium chloride (KCl) (sample 24, double arrows).
Intraperitoneal injection of 250 mM D-glucose in TG arcAb mice and
their NTG littermates (sample 5, single arrow) after 12 h of fasting
led to a sharp increase in hippocampal ECF glucose in NTG animals,
whereas the TG animals did not demonstrate such rise in glucose
levels. However, intraperitoneal injection of 250 mM D-glucose in
combination with neuronal stimulation by retrodialysis of 120 mM
KCl (sample 24, double arrows) into the hippocampal ECF both TG
and NTG animals showed an increase in glucose. d Impaired increase
in lactate concentrations in TG animals upon neuronal stimulation. No
difference in basal lactate levels was found between TG animals and
their NTG littermates (samples 1–23). Lactate was measured in the
same microdialysate samples as collected for glucose uptake analyses
(Fig. 2a). Note that intraperitoneal administration of glucose did not
have an effect on lactate concentrations (sample 5, single arrow).
Retrodialysis of 120 mM KCl (sample 24, double arrows) led to a fast
and steep increase in lactate levels in the microdialysate of NTG
animals, a response which was not found in the TG mice. The TG
animals showed slower and smaller rise in lactate and a delay in the
time to reach baseline concentrations
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Early-stage astrogliosis precedes wide-spread Ab
plaque burden and is paralleled by increased vascular
basement laminin staining and increased soluble
laminin secretion by TG arcAb astrocytes ex vivo
Astrogliosis was found in all three disease stages in TG
arcAb mice, increasing with age, especially surrounding
diffuse Ab plaques in the neuropil and vessels bearing
CAA or vascular Ab deposits. The presence of astrogliosis
in the early-stage mice was found around arteries
descending from leptomeningeal vessels and was remark-
able since only little extracellular Ab plaque burden was
present in this age group (Fig. 4a). The extensive astrogl-
iosis around these blood vessels was paralleled by an
increased immunoreactivity against laminin (Fig. 4a), a
major component of the VBM. Moreover, astrocytes
themselves were clearly immunopositive for laminin too;
especially astrocytic dendrites presented a strong laminin
staining (Fig. 4b, arrow). Laminin was concentrated
around and within the astrocytes and following the astro-
cytic staining structure rather than that for Ab (Fig. 4b).
Interestingly, a more diffuse laminin staining was observed
around astrocytes as well (Fig. 4b, asterisk). It is known
that astrocytes can secrete laminin [8] and we, therefore,
measured soluble laminin in media of TG and NTG ex
vivo-cultured astrocytes derived from early and mid-stage
arcAb mice. The TG astrocytes in both the age groups were
found to secrete more laminin than their NTG counterparts
(Fig. 4c, early-stage and d, mid-stage).
Ab induces astrocyte endfeet retraction leading
to neurovascular uncoupling, starting at early-stage
pathology
To further investigate the astrocytic abnormalities found in the
TG arcAb mice, we studied the structural appearance of
astrocyte endfeet at early and late pathological stages of the
disease (Fig. 5). As was observed in other transgenic AD
mouse models [61] we found signs of neurovascular uncou-
pling suggested by swelling and retraction of astrocyte endfeet
of astrocytes surrounding (vascular) Ab deposits in both early
and late-stage animals (Fig. 5a, b). Although the cerebro-
vasculature in late-stage arcAb mice is severely affected by
CAA, we found that on non-CAA-laden vessels in these aged
mice contacts between astrocyte endfeet and the vasculature
was maintained (Fig. 5b, arrows). An Ab-induced endfeet
detachment and swelling was further suggested by the
observation of astrocyte endfeet swelling and endfeet loss of
astrocytes surrounding diffuse Ab plaques (Fig. 5b, asterisk)
similar to CAA-induced endfeet abnormalities (Fig. 5a,
arrows). Furthermore, astrocytes surrounding the small
number of Ab deposits which were present in the early-stage
mice, all showed endfeet abnormalities.
Loss of astrocytic b dystroglycan expression
in late-stage TG arcAb mice is consistent
with decreased interactions between astrocyte endfeet
and vasculature and is paralleled by cerebral
extravasation of blood-derived IgG
Astrocyte endfeet attach to cerebral vessels via interactions
between endfeet b dystroglycan and vascular laminin [2, 53].
To understand if the observed astrocyte endfeet retractions as
shown in Fig. 5 could be associated with impaired b dystro-
glycan-laminin interactions, the expression of astrocytic b
dystroglycan was explored. We found that the astrocytic
expression of b dystroglycan was significantly decreased in
TG arcAb mice (Fig. 6a, c, e, g). Loss of b dystroglycan was
paralleled by the cerebral presence of endogenous mouse IgG
around diffuse Ab plaques (Fig. 6a, c, and e, arrows) and was
most pronounced in the cortical regions and hippocampus
(Fig. 6a, e and s). The presence of mouse IgG was detected by
the same secondary anti-mouse antibody (fluorescein iso-
thiocyanate/FITC-tagged donkey anti-mouse IgG, Jackson
Fig. 3 Expression of the astrocytic glucose and lactate transporter
involved in cerebral metabolism and neuronal functioning is reduced
in astrocytes cultured from mid-stage TG arcAb mouse brain with
concomitant decreased lactate release. a GLUT1 and MCT1 (astro-
cytic lactate transporter) were down-regulated in whole cell lysate
preparations of astrocyte cultures originating from mid-stage TG
arcAb mice. Staining for b actin served as loading control for all
samples. b Astrocytic lactate release in media of the same astrocyte
cultures originating from mid-stage TG and NTG arcAb mice. A
decreased lactate concentration was found in culture media of TG
astrocytes as compared to astrocytes from NTG littermate brains
300 Acta Neuropathol (2011) 122:293–311
123
ImmunoResearch Laboratories, USA) used to visualise the
primary anti-b dystroglycan antibody which was raised in
mouse, explaining the presence of both b dystroglycan and
endogenous mouse IgG on the same brain sections. Adjacent
brain sections immuno-stained with FITC-conjugated don-
key anti-mouse IgG secondary antibody only showed the
same IgG staining pattern (data not shown). Interestingly, an
area of the brain where no extravasated mouse IgG could be
observed (the hypothalamic region, Fig. 6c) did show a sig-
nificantly less pronounced loss of b dystroglycan expression
(Fig. 6c and g). This area was also spared from diffuse Ab
plaques and Ab was rather present as CAA.
b-amyloid-related pathology of cerebral arteries
and arterioles in late-stage arcAb mice
Vascular corrosion casts and SEM were used to study the
vascular morphology in brains of TG and arcAb NTG mice.
Severe alterations were seen especially in the morphology of
arteries and arterioles of late-stage TG animals as compared
Fig. 4 Intensive astrogliosis with concomitant laminin over-expres-
sion is already present in the early-stage TG arcAb mouse brain.
a Representative cortical brain section of an early-stage TG arcAb
mouse triple-stained for GFAP, laminin and Ab/APP. Only few
diffuse Ab plaques and little vascular Ab deposits were seen at this
age. However, the presence of astrogliosis (GFAP staining) around
some incoming leptomeningeal vessels and arterioles (a, arrows) and
small vessels (a, asterisks) in the cortex was already detected at this
age with a concomitant increased immunopositivity for laminin. b A
920 of a representative cortical brain section of an early-stage TG
arcAb mouse triple-stained for GFAP, laminin and Ab/APP. Astro-
cyte (GFAP) and laminin staining showed expression and/or secretion
of laminin in the astrocytic dendrites (arrows) and surrounding the
astrocytes (asterisk). Western blots showing a higher amount of
laminin in the media of ex vivo astrocyte cultures from early-stage
(c) and mid-stage (d) TG arcAb mice as compared to that of
astrocytes from their NTG littermates. Scale bar a 300 lm; b 30 lm.
Hue settings of fluorescence for Ab were altered for more contrast
effect explaining the purple colour
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to their NTG littermates (Fig. 7). The clear and typically-
shaped endothelial imprints as seen in the NTG littermates
(Fig. 7a, arrow) were malformed and often abolished in the
TG mice (Fig. 7b, arrow). Furthermore, the vessel walls of
these arteries and arterioles had a tree bark-like appearance
(Fig. 7b, arrow). Severe vessel constrictions, appearing as
stenoses, were found on numerous arteries and arterioles
(Fig. 7b, asterisks and inset). Protrusions of the perfusion
resin were found both on arterioles and capillaries of TG
animals, indicating leakage of the vessel walls (Fig. 7c). In
addition to these changes in vessel morphology, gaps in the
vascular bed were uniquely present in the TG animals
(Fig. 7d). Cerebrovascular morphology of early and mid-
stage TG animals was not altered as compared to their NTG
littermates (data not shown).
Cerebral hypoperfusion and small cerebral vessel
leakages without significant haemorrhaging
in late-stage arcAb mice
Mouse brains perfused with casting resin and processed for
histological analyses, showed that the presence of vessel
leakages was paralleled by CAA in the TG animals
(Fig. 8b, asterisks). These leakages appeared as ball-
shaped structures protruding out of the vessel wall, similar
to the structures observed in the SEM pictures (Fig. 7d).
Resin protrusions were not found on vessels of NTG lit-
termates (Fig. 8a). The number of vessels perfused with
fluorescent casting resin was lower in the TG animals
(Fig. 8b, frame and Fig. 8c) as compared to their NTG
littermates (Fig. 8a, frame and Fig. 8c). This was not
accompanied by a reduction in vascular density (Fig. 8b
GLUT1, frame and Fig. 8d) indicating that the decrease in
vascular casting resin penetration was most likely due to
the pathological cerebral hypoperfusion in the TG animals.
Decreased cerebral perfusion could also explain the gaps in
the vascular bed in the TG mice as observed with SEM
(Fig. 7d). To assess if casting resin protrusions could be a
sign of BBB compromise, TG and arcAb NTG mice were
intraperitoneally injected with Trypan Blue. Unlike the
results seen with the vascular casting resin (Fig. 8) such
Trypan Blue-albumin (TBA) extravasations were mainly
found around small vessels (Fig. 9a, asterisks). Bigger
arterioles and arteries showed a mere accumulation of TBA
Fig. 5 Diffuse and vascular Ab deposits induce astrocyte endfeet
retraction and swelling in TG arcAb mice, starting at early-stage
pathology. a Representative confocal microscopy images of cortical
brain sections of an early-stage TG arcAb mouse triple-stained for
GFAP, laminin and Ab/APP. At this age, TG arcAb mice have only
few diffuse Ab plaques and very little CAA but the structural
appearance of these Ab deposits is similar to that in mid-stage and
late-stage animals, albeit less dense and restricted in size. Astrocytes
(GFAP) surrounding these plaques show swollen endfeet (a, arrows
and asterisk) and loss of endfeet contact at CAA-affected vessels
(laminin was used as vessel marker). b Arrows in sections show close
endfeet—vessel interactions at a non-CAA-affected vessel in a late-
stage TG arcAb mouse brain. The same endfeet retractions and
swellings as can be seen in a were observed for astrocytes within and
surrounding diffuse Ab plaques (b, asterisk). Scale bar a 30 lm;
b 150 lm. Hue settings of fluorescence for Ab were altered for more
contrast effect explaining the blue colour
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within the vessel wall (Fig. 9a plus sign and arrow,
respectively). Similar to the vascular resin histology
(Fig. 8) these small vessel TBA extravasations and arterial/
big arteriolar TBA accumulations were only present on
CAA-affected vessels (Fig. 9a). Vessels were visualised
using a CD31 antibody to stain endothelial cells.
Unlike TBA extravasations, cerebrovascular haemor-
rhages as detected by Prussian Blue staining were rarely
seen but likewise associated with CAA (Fig. 9b, asterisk
and 9c) with brain areas presenting abundant CAA, e.g.
(pre-) frontal cortex, mainly affected. However, the extent
of haemorrhagic lesions did not correlate with the severity
degree of CAA. Furthermore, casting resin protrusions
were not chronically paralleled by haemorrhages (Fig. 9d,
arrows).
CAA-dependent abnormalities of vascular basement
membranes and degeneration of smooth muscle cells
in late-stage arcAb mice
Brains from littermates of the mice used in the SEM
vascular corrosion casts (Fig. 7) and which were not
perfused with casting resin were processed for immu-
nohistochemistry to analyse the morphological alterations
found by SEM. Laminin staining (Fig. 10a) was used as
VBM/vessel marker and its expression found to be sig-
nificantly increased on CAA-laden vessels in mid- and
late-stage TG arcAb mice (Fig. 10c, d), a phenomenon
underlying VBM thickening and well known to occur in
AD [16]. Bulges of laminin (Fig. 10a, asterisks) resem-
bling the stenoses observed in the SEM analyses
(Fig. 7b, asterisks) and vessel constrictions (Fig. 7c,
arrow and Fig. 10a, plus signs) were widely found in the
TG animals. Moreover, these vascular malformations
Fig. 6 Astrocytic b dystroglycan expression is significantly
decreased in late-stage TG arcAb mouse brain and paralleled by
IgG extravasation. Representative images of late-stage TG (a, c,
e) and arcAb NTG littermate (b, d, f) mice showing decreased
expression of the astrocyte endfeet protein b dystroglycan in TG
arcAb mouse brain as compared to their NTG littermates. Loss of b
dystroglycan immunoreactivity was most pronounced in the cortex
(a) and hippocampus (e) of TG animals. This reduced expression was
paralleled by the presence of cerebral extravasation of endogenous
IgG around diffuse Ab plaques (a, e, arrows). Areas of the brain
(hypothalamic region) where no mouse IgG could be observed did
show less pronounced loss of b dystroglycan expression (c). These
areas were also not affected by diffuse Ab plaques but rather by CAA.
Scale bar a 300 lm. Presence of mouse IgG was detected by the same
secondary anti-mouse antibody (FITC-tagged donkey anti-mouse
IgG) used to visualise primary anti-b dystroglycan antibody which
was raised in mouse, explaining the presence of both b dystroglycan
and endogenous mouse IgG on the same brain sections. g Significant
loss of b dystroglycan expression on blood vessels in cortex (ctx),
hippocampus (hipp) and hypothalamic region (hypthal) of late-stage
TG arcAb mice compared to NTG littermates. The hypothalamic
region of TG arcAb mice showed significantly more b dystroglycan
expression as compared to cortex and hippocampus (p \ 0.02) but
was still significantly less than in NTG littermates (p \ 0.001). b
dystroglycan immunoreactivity was calculated by measuring staining
intensity using ImageJ software. Student’s t test, n = respective brain
areas of 12 mice (6 TG and 6 NTG), three sections/brain area/mouse.
Hue settings of fluorescence for Ab were altered for more contrast
effect explaining the purple colour
b
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were co-localised with CAA present on the vessels
(Fig. 10a). Those parts of the same vessels without CAA
appeared to be normal and showed no increase in lam-
inin immunoreactivity (Fig. 10a, arrows), indicating a
relationship between CAA and the morphological alter-
ations seen in the SEM analyses (Fig. 7). Severe CAA as
uniquely observed in late-stage TG arcAb mice
(Fig. 10b) caused not only such strong laminin up-reg-
ulation in the VBM but lead to rupture of the vessel wall
as well (Fig. 10b, arrow). In addition, dust-like laminin
particles surrounding the ruptured vessels were abun-
dantly observed (Fig. 10b, asterisk). NTG littermates
presented typical laminin immunoreactivity of the VBM
(Fig. 10b).
Congophilic amyloid angiopathy strongly and signifi-
cantly affected the expression of vascular SMCs in late-
stage TG animals with SMC loss paralleled by interrup-
tions in SMC strata (Fig. 11a, arrows and Fig. 11c). In
contrast, non-CAA-affected vessels presented intact,
uninterrupted vascular SMC layers similar to vessels of
their NTG littermates (Fig. 11b).
Discussion
Vascular pathology is a critical and more and more
recognised component of AD, impairing blood-to-brain
influx of nutrients essential for cerebral functioning and
brain-to-blood efflux of cerebral waste products leading to
cognitive deterioration [10, 11, 64, 65]. By characterising
the transgenic arcAb mouse model of AD—which presents
a strong vascular pathology—at early, mid and late disease
stages we investigated what processes could possibly
instigate the vascular and metabolic impairments early on
in the disease and which mechanisms aggravate the vas-
cular pathology at later stages in this AD mouse model.
Decreased endothelial GLUT1 expression has been found
in transgenic mouse models of AD and in human AD
patients [15, 22, 26, 47]. We observed lowered GLUT1
protein expression in TG animals starting at mid-stage
disease pathology when CAA formation is apparent in
these mice and diffuse Ab plaques are becoming wide-
spread. As GLUT1 is the sole glucose transporter expres-
sed by brain endothelial cells and peripheral supply is the
Fig. 7 Morphological alterations of the cerebrovasculature in late-
stage TG arcAb mice. Scanning electron microscopy (SEM) of late-
stage arcAb NTG littermates showed clear and regular endothelial
cell imprints on arterial vessel walls (a, arrow) and a smooth
appearance of the vessel wall. In contrast, late-stage TG arcAb mice
presented a tree bark-like vessel wall and degenerated, often absent
endothelial cell imprints (b, arrow). Furthermore, extensive stenoses
and bulging of the vessel wall were observed both on arteries and
arterioles (b, asterisks and inset). Ball-shaped leakages of the
perfusion resin were found on arteries, arterioles and capillaries of
the TG arcAb mice (c, arrows). Loose vessel ends were observed as
well (c, asterisk). Whereas the NTG littermates showed a dense and
constant vascular bed, the density of the vascular bed in the TG
animals was reduced showing numerous gaps, especially in the area
of the temporal lobe (d, arrows). Scale bar a 100 lm; b and c 50 lm;
d 1 mm
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principal source of glucose for the brain [46], it can be
appreciated that a decrease in GLUT1 expression will have
significant outcomes on cerebral glucose uptake. Indeed,
cerebral imaging data from human subjects show a clear
correlation between GLUT1 expression and blood-to-brain
glucose uptake [12]. Our findings of decreased brain
glucose influx and concentration as measured by in vivo
microdialysis in TG arcAb mice, are in line with these data.
The majority of glucose entering the brain via endothelial
GLUT1 is subsequently taken up by astrocytes via astro-
cytic GLUT1 [46]. Astrocyte pathology with altered
expression of astrocyte-specific proteins essential for
cerebral functioning and metabolism is recognised as a
significant factor in AD and subject to intensive research
[3, 48]. To understand if a decreased astrocytic GLUT1
expression could also be an underlying factor in the
reduced glucose uptake in our microdialysis studies, we
cultured astrocytes from the same cohort of arcAb mice ex
vivo. We found that its expression was severely affected,
starting at mid-stage disease pathology. Astrocytic glucose
uptake is a vital step in the cerebral energy apparatus
because astrocytes convert glucose into lactate which is
used by neurons during neuronal stimulation [14, 29, 38,
43, 44]. Abnormalities in this essential astrocytic contri-
bution to neurometabolic coupling have detectable
outcomes on cerebral performance and are known to occur
Fig. 8 Leakages of the cerebrovasculature and cerebral hypoperfu-
sion in late-stage TG arcAb mice. Brains of littermates of the TG and
arcAb NTG mice used for SEM (Fig. 7) were processed for
histological purposes after perfusion with vascular casting resin.
Perfusion of the cerebrovasculature with the vascular casting resin
showed adequate penetration of arteries and smaller vessels
(a, frame). TG littermates showed casting resin leakages similar to
those observed with SEM (Fig. 7d) (b, asterisks). Perfusion of the
cerebrovasculature with casting resin was, in contrast to the NTG
littermates (a, frame), significantly impaired in the cortex showing
areas lacking fluorescent casting resin and hence resin-negative
vessels (b, frame and c). An eventual hypoperfusion due to reduced
vascular density was excluded by the finding of GLUT1-positive
endothelium in the non-perfused brain areas (b, frame and d). Scale
bar a 150 lm. Hue settings of fluorescence for Ab were altered for
more contrast effect explaining the purple colour
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in AD [3, 50]. The impaired lactate release we observed
upon in vivo neuronal stimulation during microdialysis in
TG arcAb mice, was confirmed by a decreased astrocytic
MCT1 expression and lactate release deficiency ex vivo.
The reciprocal character of the expression profiles of
MCT1 and GLUT1 as shown by Maurer and colleagues
[33] makes plausible that the decreased astrocytic MCT1
protein levels could be related to lower astrocytic GLUT1.
Astrocytic GLUT1 and MCT1 are mainly expressed on
astrocyte endfeet which are crucial for neurovascular
coupling [1, 3, 65]. Impaired neurovascular coupling is
common in neurodegenerative disorders including AD and
AD mouse models with astrocyte endfeet retraction and
swelling compromising the cross-talk between astrocytes,
blood vessels and neurons and decreased cerebral metab-
olism as histological and functional hallmarks [3, 37, 61].
Fig. 9 In vivo leakages of the cerebrovasculature in late-stage TG
arcAb mice are not paralleled by haemorrhages, suggesting small
BBB disruptions. a Intraperitoneal injection of late-stage TG mice
and their arcAb NTG littermates with Trypan Blue showed extrav-
asations of Trypan blue mainly around small vessels in the TG
animals (asterisks). Bigger arterioles (a, plus sign) and arteries
(a, arrow) were found to accumulate Trypan Blue within the vessel
wall. Both small vessel extravasation and arterial accumulation of
Trypan Blue within the vessel wall was only seen for vessels affected
by CAA. Scale bar a 150 lm. Hue settings of fluorescence for Trypan
Blue were altered for more contrast effect explaining the blue colour.
(b) Thioflavin S staining (green-yellow) combined with Prussian Blue
staining (dark blue, asterisk) showed CAA-related presence of
haemorrhages. Scale bar b 30 lm. The number of haemorrhages
was significantly lower than Trypan Blue extravasations (c) and not
chronically paralleled by vascular casting resin protrusions (d). Scale
bar d 150 lm
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We detected signs of neurovascular uncoupling represented
by astrocyte endfeet retraction and swelling, possibly also
(partly) explaining our findings on impaired metabolism.
We observed this starting at an early pathological stage of
the disease, at which extracellular Ab plaque burden is
small in the arcAb mouse. Only astrocytes surrounding
diffuse Ab plaques and vascular Ab deposits showed
endfeet abnormalities even at the late-stage pathology,
suggesting that Ab instigates the loss of neurovascular
coupling rather than the process of ageing or the mere
presence of the APP transgene in these mice. The mecha-
nism by which Ab prevents contact between endfeet could
be the formation of a physical barrier between blood ves-
sels and astrocytes. Another likely mechanism underlying
this impaired astrocyte-endothelium interaction could be
the loss of expression of the astrocyte endfeet—VBM
linker b dystroglycan as we observed in our TG arcAb
mice [2, 53]. It is unclear whether Ab toxicity is involved
in the attenuated b dystroglycan expression or that the
changes in the VBM we describe here and were described
by others [21] are culprit. Interestingly, however, the
degree of b dystroglycan loss was paralleled by the pres-
ence of diffuse, parenchymal Ab plaques and leakage of
endogenous IgG into the brain. Astrocyte endfeet form an
essential part of the BBB [1] and the question is if
detachment of astrocyte endfeet from the vasculature
leading to disruption of the BBB and hence extravasation
of serum proteins into the CNS or that entry of serum
proteins into the brain is responsible for this aspect of
neurovascular uncoupling. Brains of multiple sclerosis
patients and its in vivo counterpart experimental autoim-
mune encephalomyelitis show that neuroinflammation and
extravasation of components of the peripheral immune
system induce astrocyte endfeet abnormalities including
Fig. 10 Vascular basement membrane abnormalities in mid and late-
stage TG arcAb mice. Constrictions/stenoses (a, plus signs) and
localised thickening of the vessel walls (a, asterisks) were abundantly
seen on CAA-laden vessels in brains of late-stage TG arcAb mice.
These basement membrane irregularities due to laminin over-expres-
sion (a) were confined to those parts of the cerebral vessels that were
affected by CAA; all other parts showed normal laminin expression
and smooth vessel wall appearance (a, arrows). Severe CAA in late-
stage TG arcAb mice (b) caused both intense and significant increase
in laminin immunopositivity and rupture of the vascular basement
membrane laminin (b, arrow; c and d). In addition, dust-like laminin
particles could be observed surrounding the affected vessel (b,
asterisk). Cerebral vessels of arcAb NTG littermates lacked CAA and
vascular basement membranes showed typical laminin immunoposi-
tivity (b, last two image sets). Scale bar a 150 lm; b 30 lm. Hue
settings of fluorescence for Ab were altered for more contrast effect
explaining the blue colour
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retraction and swelling [2, 63]. It is well established that
CNS entry of components of the peripheral immune system
is part of the AD pathology [13]. Taking into account our
findings on the pathological cerebral extravasation of the
BBB viability marker Trypan Blue and vessel wall insta-
bility as shown by leakage of vascular casting resin in the
TG arcAb mice, a role for components of the peripheral
immune system in (further) triggering pathological astro-
cyte responses including endfeet retraction could indeed be
possible [1, 13, 65]. It is clear that with astrocyte endfeet
abnormalities already present at the early-stage pathology,
impaired BBB functioning is a premature process in the
arcAb mouse. An astrocytic involvement at premature time
points in the pathology was further indicated by astrogli-
osis with paralleled increase in vascular laminin and
astrocytic laminin secretion ex vivo in the early-stage mice.
Increase in laminin VBM in these relatively young mice
with little Ab plaque burden seems to be contradictory with
the unique CAA-related increase in laminin we found in
mid-stage and late-stage mice. It is interesting, however,
that mainly the incoming arteries from leptomeningeal
origin showed this increased astrocyte activation in the
early-stage TG mice with concomitant increase in VBM
laminin. It is exactly these vessels which are the first to be
affected by CAA at later disease stages in the arcAb mouse
and other transgenic AD mouse models [58, 59]. The
induction of signal transduction cascades within the
endothelium can trigger astrocytic release of endothelium-
protective molecules [1]. This protective reaction could be
elicited by soluble Ab species which are known to induce
astrocyte activation and to be toxic to endothelial cells and
SMCs [18, 51, 56, 60]. Furthermore, laminin expression is
known to be up-regulated by damage to the vasculature [4,
65]. Soluble Ab species mainly as toxic protofibrils are
abundantly present in arcAb mice from 2 months of age
onwards [31, 35] and could be directed to the vasculature
by the forces of the cerebrovascular drainage pathways in
which especially the cerebral arteries are involved [9, 20,
58], providing a possible explanation for the unique loca-
tion of these reactive astrocytes around blood vessels. Seen
in this light, laminin is known to interact with Ab, inhib-
iting its fibrillisation and diluting its neurotoxicity [27, 36],
Fig. 11 Vascular smooth
muscle cells are degenerated
and severely affected in CAA-
laden cerebral vessels in late-
stage TG arcAb mice. CAA-
laden arteries and arterioles in
late-stage TG arcAb mice
showed a characteristic
thickening of the laminin
basement membrane (a, upper
arrows) and dust-like laminin
particles were regularly
observed (a, lower arrow).
Vascular SMC layers were
severely degenerated or
completely absent (a, asterisk
and arrows; c). In contrast,
NTG littermates were found to
have a typical laminin basement
membrane thickness (b) and an
intact, uninterrupted vascular
SMC stratum (b, arrow and
asterisk). Plus signs in a show
presence of mouse IgG which
was detected by the same
secondary anti-mouse antibody
(FITC-tagged donkey anti-
mouse IgG) used to visualise
primary anti-smooth muscle
actin antibody which was raised
in mouse, explaining the
presence of both smooth muscle
cell and endogenous mouse IgG
on the same brain sections.
Scale bar a 150 lm
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giving foundation to the idea that astrocytic laminin release
as we detected could be a protective mechanism to both
strengthen the vessel wall by increasing VBM thickness
and an attempt to reduce Ab-induced neuro- and vascular
toxicity by interfering with (further) Ab fibrillisation.
Although we found astrocytes to secrete laminin as was
observed by others as well [8, 45], it cannot be excluded
that endothelial cells themselves are involved too as these
cells can secrete laminin [19]. Although possibly being an
astrocytic protection attempt, an increase in laminin
secretion paralleled by VBM thickening leads to vessel
wall rigidity and hence reduced CBF, especially the lep-
tomeningeal vessel wall thickening we observed in early-
stage TG arcAb mice which directly affects downstream
perfusion of the arterioles and capillaries [23, 30]. Cerebral
hypoperfusion—and with that reduced oxygen and glucose
supply and hindered cerebral drainage of cerebral waste
products—starting at such early age could be at the base of
the accumulation of Ab and the severe CAA-related vas-
cular pathology with vascular SMC loss and BBB
impairments as we observed later on at mid- and late-stage
pathology in the arcAb mice.
Together, our data underscore the role of the impaired
brain vascular system accompanying b-amyloid pathology
[4, 7, 17, 59, 64] and they establish that astrocytes are
already involved early on in the disease in arcAb mice,
with further age-related progression in severity. Further,
our data suggest that impaired functions of astrocytes
related to cerebral energy deficits may contribute to
decreased neuronal and vascular functions followed later
by pathological stages of b-amyloid pathology in arcAb
mice.
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